bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2018: O S A J J M A M F J
2017: D N O

 
  Other news for:
Abnormalities
Pregnancy
Pregnancy Complications
Methylphenidate
 Resources from HONselect
Ritalin During Pregnancy May Raise Risk of Heart Defect in Baby

By Robert Preidt

WEDNESDAY, Dec. 13, 2017 (HealthDay News) -- If you take Ritalin or Concerta for attention-deficit/hyperactivity disorder (ADHD) and you plan to become pregnant, you might want to talk to your doctor about switching your medication first.

A new study found a small increased risk of having a baby with a heart defect if Ritalin/Concerta (methylphenidate) was taken by the mother-to-be. However, taking amphetamines for ADHD did not carry the same risk, researchers said.

"Our findings suggest a small increase in the risk of cardiac malformations associated with first-trimester exposure to methylphenidate, but not to amphetamines," said study author Krista Huybrechts. She with Brigham and Women's Hospital's division of pharmacoepidemiology and pharmacoeconomics, in Boston.

"This information may be important to patients and their physicians as they weigh the risks and benefits of alternative treatment strategies for attention-deficit/hyperactivity disorder," she added in a hospital news release.

However, while the study found an association, it did not prove that taking Ritalin during pregnancy actually caused the risk of heart defects to rise.

In the study, the researchers analyzed data from 1.8 million pregnancies in the United States and 2.5 million pregnancies in five Nordic countries.

Specifically, taking methylphenidate in the first trimester was associated with a 28 percent higher risk of heart defects. That means that for every 1,000 women who take methylphenidate during the first trimester, there would be three additional infants born with congenital heart defects.

"Our study markedly expands the evidence base regarding the safety of methylphenidate use in pregnancy," Huybrechts said. "Although the absolute risk is small, it is nevertheless important evidence to consider when treating young women of reproductive age and pregnant women."

The study was published Dec. 13 in the journal JAMA Psychiatry.

More information

The U.S. Centers for Disease Control and Prevention has more on congenital heart defects.

SOURCE: Brigham and Women's Hospital, news release, Dec. 13, 2017

Copyright © 2017 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=729355

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Methylphenidate
Risk
Heart
Women
Amphetamines
Research Personnel
Heart Defects, Congenital
Association
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact